Out of 2 analysts covering Inovio Pharma (NASDAQ:INO), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. $18 is the highest target while $14.0 is the lowest. The $16 average target is 73.54% above today’s ($9.22) stock price. Inovio Pharma has been the topic of 3 analyst reports since January 5, 2016 according to StockzIntelligence Inc. Maxim Group downgraded the stock on August 9 to “Hold” rating. Below is a list of Inovio Pharmaceuticals Inc (NASDAQ:INO) latest ratings and price target changes.
09/08/2016 Broker: Maxim Group Old Rating: Buy New Rating: Hold Downgrade
14/03/2016 Broker: Brean Capital Rating: Buy Old Target: $20.00 New Target: $18.00 Maintain
About 1.02M shares traded hands. Inovio Pharmaceuticals Inc (NASDAQ:INO) has risen 54.50% since February 8, 2016 and is uptrending. It has outperformed by 38.01% the S&P500.
Inovio Pharmaceuticals, Inc. is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The company has a market cap of $737.81 million. The Company’s DNA immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It currently has negative earnings. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.